Product Information

NEVIRAPINE ER 400 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $1.5213 per EA under NDC 00378489093. Its NADAC has been published 473 times since Dec 3, 2014.

FDA first approved this application on Oct 27, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

NEVIRAPINE ER 400 MG TABLET

nevirapine
$1.5213per EA

Strength

400 mg/1

NDC

00378489093

Classification

Generic

Dosage Form

TABLET, EXTENDED RELEASE

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

NEVIRAPINE

Approval Type

Generic (ANDA)

FDA Application

ANDA205651

FDA Approved

10/27/2014

TE Code

AB

On Market Since

10/29/2014

Pharmacological Classes

Cytochrome P450 2B6 Inducers
Cytochrome P450 3A Inducers
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Non-Nucleoside Analog
Non-Nucleoside Reverse Transcriptase Inhibitors

Price Statistics

The NADAC for NEVIRAPINE ER 400 MG TABLET has been published 473 times since Dec 3, 2014, and over the history we have for it it has declined 90.8%. The table below summarizes its recorded NADAC range and movement.

Current price$1.5213 per EA
All-time high$18.0781 (Jul 15, 2015)
All-time low$1.2487 (Jan 21, 2026)
52-week high$1.9836
52-week low$1.2487
Median price$5.9065
Average price$7.0467
Largest weekly change-59.4% (Apr 17, 2024)
Weeks tracked473
Tracking sinceDec 3, 2014

Price History

1W

+0.8%

1M

+0.8%

3M

-3.9%

6M

+17.3%

1Y

-23.3%

3Y

-64.6%

5Y

-64.6%

All

-90.8%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the nevirapine market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of NEVIRAPINE ER 400 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for NEVIRAPINE ER 400 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $1.5213 per EA (NDC 00378489093), effective Aug 19, 2026.

How has the price of NEVIRAPINE ER 400 MG TABLET changed over time?

Over the history we have for it, the NADAC for NEVIRAPINE ER 400 MG TABLET has declined 90.8%. It has been tracked across 473 weekly CMS publications since Dec 3, 2014.

What are the highest and lowest recorded NADAC prices for NEVIRAPINE ER 400 MG TABLET?

Since Dec 3, 2014, the NADAC for NEVIRAPINE ER 400 MG TABLET has ranged from a low of $1.2487 (Jan 21, 2026) to a high of $18.0781 (Jul 15, 2015), with a median of $5.9065 per EA.

Are there cheaper alternatives to NEVIRAPINE ER 400 MG TABLET?

No other NADAC-published product currently shares the active ingredient and strength of NEVIRAPINE ER 400 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures NEVIRAPINE ER 400 MG TABLET?

NEVIRAPINE ER 400 MG TABLET (NDC 00378489093) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.